Cardiovascular protection by anti-inflammatory statin therapy.
Statins are widely used in the prevention of atheromatous disease and its complications. While their lipid lowering effects are very important, there is increasing emphasis on the other effects of statins described as pleiotropic. These include atheromatous plaque stabilisation generally ascribed to their anti-inflammatory properties. It is increasingly clear that perioperative cardiac events relate to both haemodynamic perturbations (with imbalance between oxygen demand and oxygen supply to the myocardium), and rupture/disruption of atheromatous plaques. Thus, the effects of statins on perioperative cardiac outcome have been studied, mostly in observational studies. The majority of the studies have shown benefits of statin therapy. The reason for these reported benefits is the anti-inflammatory properties of statins in the face of the known release of such mediators during major surgery, leading to plaque disruption and major adverse cardiac events. To date there are too few randomised controlled studies to recommend the prophylactic administration of statins preoperatively, yet the cohort studies are suggestive of benefits.
Howard-Alpe
Georgina
G
Nuffield Department of Anaesthetics, Oxford University, UK.
Foëx
Pierre
P
Biccard
Bruce
B
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003324:Coronary Artery Disease / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007431:Intraoperative Complications / Q000209:etiology / Q000517:prevention & control*; D019990:Perioperative Care / Q000379:methods*; D011183:Postoperative Complications / Q000517:prevention & control
D000893:Anti-Inflammatory Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors